タカナシ　ジユンイチ   TAKANASHI Jiyun'ichi   髙梨　潤一    所属   医学部 医学科（附属八千代医療センター）    職種   教授
言語種別	英語
発表タイトル	Efficacy of lacosamide for paroxysmal kinesigenic dyskinesia with auditory abnormalities associated with carbamazepine
会議名	第68回日本小児神経学会学術集会
学会区分	全国規模の学会
発表形式	ポスター掲示
講演区分	一般
発表者・共同発表者	◎SANO Kentaro, OMATA Taku, SUDOU Manami, TAKASE Nanako, TAKAHASHI Madoka, SHIOTA Megumi, SHIRATO Yuri, TAKANASHI Jun'ichi
発表年月日	2026/06/04
開催地 （都市, 国名）	Utsunomiya, Tochigi, Japan
開催期間	2026/06/04～2026/06/06
概要	Introduction: Paroxysmal kinesigenic dyskinesia (PKD) is characterized by choreoathetosis and dystonia attacks occurring at the onset of exercise. Carbamazepine (CBZ) is often effective, but some patients cannot continue treatment due to side effects such as auditory abnormalities. We report three cases of PKD children who developed auditory abnormalities with CBZ and achieved good outcomes after switching to lacosamide (LCM). Case reports: Patient 1 is 13-years-old male. The attacks of PKD occurred at age 11. He has no history of infantile convulsions. His father had a history of PKD. CBZ resolved attacks at age 12, but was switched to LCM due to the side effect of “hearing sounds a semitone lower.” Patient 2 is 14-years-old male. The attacks of PKD occurred at age 10. He and his mother and sister had a history of infantile convulsions. CBZ resolved attacks at age 13 but was switched to LCM due to the same side effect as patient 1. Patient 3 is 15-years-old male. The attacks of PKD occurred at age 13. He has no history or family history of PKD or infantile convulsions. After starting CBZ at age 15, he began “hearing sounds distortedly”. CBZ was continued because attacks were well controlled but was switched to LCM due to drug eruptions. In all cases, attacks were resolved within a few days after initiating LCM, with no recurrence of auditory abnormalities or other adverse events. Dosage was maintained at 100 mg/day in all patients. Prior to using LCM, oral informed consents were obtained from all patients and their parents regarding that LCM for PKD was off-label use. Conclusion: LCM is an effective treatment for pediatric PKD and may serve as an alternative when side effects of CBZ such as auditory abnormalities are problematic.